Product Information
FOSINOPRIL-HYDROCHLOROTHIAZIDE 10-12.5 MG TAB is a generic product labeled by Cipla USA Inc., priced at $0.6342 per EA under NDC 69097097207. Its NADAC has been published 177 times since May 17, 2023.
FDA first approved this application on Jul 9, 2009. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
10; 12.5 mg/1; mg/1
Manufacturer
Cipla USA Inc.NDC
69097097207
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDEApproval Type
Generic (ANDA)
FDA Application
ANDA090228FDA Approved
7/9/2009
TE Code
AB
On Market Since
7/24/2020
Pharmacological Classes
Price Statistics
The NADAC for FOSINOPRIL-HYDROCHLOROTHIAZIDE 10-12.5 MG TAB has been published 177 times since May 17, 2023, and over the history we have for it it has risen 95.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6342 per EA |
|---|---|
| All-time high | $0.6342 (Sep 30, 2026) |
| All-time low | $0.3243 (May 17, 2023) |
| 52-week high | $0.6342 |
| 52-week low | $0.3628 |
| Median price | $0.4782 |
| Average price | $0.4624 |
| Largest weekly change | +85.8% (Apr 17, 2024) |
| Weeks tracked | 177 |
| Tracking since | May 17, 2023 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Cipla USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Fosinopril Sodium and Hydrochlorothiazide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin Converting Enzyme Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FOSINOPRIL-HYDROCHLOROTHIAZIDE 10-12.5 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for FOSINOPRIL-HYDROCHLOROTHIAZIDE 10-12.5 MG TAB, manufactured by Cipla USA Inc., is $0.6342 per EA (NDC 69097097207), effective Sep 30, 2026.
How has the price of FOSINOPRIL-HYDROCHLOROTHIAZIDE 10-12.5 MG TAB changed over time?
Over the history we have for it, the NADAC for FOSINOPRIL-HYDROCHLOROTHIAZIDE 10-12.5 MG TAB has risen 95.5%. It has been tracked across 177 weekly CMS publications since May 17, 2023.
What are the highest and lowest recorded NADAC prices for FOSINOPRIL-HYDROCHLOROTHIAZIDE 10-12.5 MG TAB?
Since May 17, 2023, the NADAC for FOSINOPRIL-HYDROCHLOROTHIAZIDE 10-12.5 MG TAB has ranged from a low of $0.3243 (May 17, 2023) to a high of $0.6342 (Sep 30, 2026), with a median of $0.4782 per EA.
Are there cheaper alternatives to FOSINOPRIL-HYDROCHLOROTHIAZIDE 10-12.5 MG TAB?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as FOSINOPRIL-HYDROCHLOROTHIAZIDE 10-12.5 MG TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures FOSINOPRIL-HYDROCHLOROTHIAZIDE 10-12.5 MG TAB?
FOSINOPRIL-HYDROCHLOROTHIAZIDE 10-12.5 MG TAB (NDC 69097097207) is labeled by Cipla USA Inc., and CMS classifies it as a generic product.